📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Digital_Lyo

Lead Participant: LYOSENZ LTD

Abstract

The number of biopharmaceutical injectable products continues to increase. Predictions are that 40 per cent of new molecular entities will require batch freeze-drying for stability. The freeze-drying process (lyophilization) removes water from sensitive or high-value products such as vaccines, biologics, antibiotics, to extend shelf-life without the need for refrigeration/cold-chain. Freeze-drying processes need to be sustainable and commercially viable. There is a need to accelerate batch throughput and build capacity to increase efficiency and enable timely response to unexpected demand (e.g. COVID-19). Shortening drying times reduces energy demands and emissions and improves efficiency so lowering end-product costs. This aligns with the Clean Growth Strategy.

A pharmaceutical product development programme involves optimisation of formulations and processes for product viability and consistency; but product quality issues are identified at the end of a long cycle and at this stage significant costs have already been incurred. In-situ rapid analytical monitoring, giving real-time automated data, will provide feedback on and enable control of the lengthy freeze-drying process. Such insight can enable shortening of development times, reduced repeat runs and product failure/loss, lessened environmental costs and bioburden and ultimately improved product quality and consistency.

Freeze-drying employs high-global warming potential (GWP) refrigerants (banned 2030) or liquid nitrogen (high energy use in manufacture) for cooling, and improving sustainability requires a fresh approach. Implementation of a continuous freeze-drying Peltier system would be capable of a step change reduction in emissions. Further, freeze-drying processes must be repurposed for the expected increase in personalised medicines and the smaller batch runs and 'just-in-time' production schedules that this involves.

By building a consortium encompassing diverse expertise in key areas we have identified multiplexed Process Analytical Technology (PAT) to provide the required rapid data for modelling the freeze-drying process. Such coupled PAT sensor technology will enable scrutiny and control of batch freeze-drying and enable future continuous freeze-drying processes. Anticipated CO2 savings are in the order of 700 tonnes per newly developed product, achieved by reduced development cycles and increased production efficiencies in the order of 1 per cent. This is equivalent to savings of CO2 emissions of 300 tonnes per year per freeze-dryer.

This innovative multiplexed approach offers insight potential for in-depth analysis of factors impacting batch manufacturing freeze-drying efficiency. It further affords the opportunity to enhance process understanding of the freezing and drying stages to de-risk the deployment of new continuous manufacturing techniques, and ultimately maximise their efficiency and sustainability.

Lead Participant

Project Cost

Grant Offer

LYOSENZ LTD £136,467 £ 95,527
 

Participant

MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY £84,168 £ 84,168
QROMETRIC LIMITED £228,717 £ 160,102
SIEMENS INDUSTRY SOFTWARE LIMITED £50,330 £ 25,165
ASTRAZENECA PLC £98,173
DE MONTFORT UNIVERSITY £399,737 £ 399,737
IS-INSTRUMENTS LIMITED £221,655 £ 155,158
MICRON DESIGN LIMITED £112,256 £ 78,579

Publications

10 25 50